Data for the phase 2a first-in-human study of Eyesight RPE for dry AMD will be submitted by Eyestem to DCGI.

Data for the phase 2a first-in-human study of Eyesight RPE for dry AMD will be submitted by Eyestem to DCGI.

The Drugs Controller General of India (DCGI) will receive data from Eyestem for approval of a phase 2a first-in-human research for its product called Eyesight RPE for dry age-related macular degeneration (AMD). The approval will mark a key turning point…